Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2008-03-11
2008-03-11
Woodward, M P (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S489000, C424S417000, C424S420000
Reexamination Certificate
active
10842977
ABSTRACT:
The small particle liposome aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes. The liposomes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration.
REFERENCES:
patent: 4963367 (1990-10-01), Ecanow
patent: 5049388 (1991-09-01), Knight et al.
patent: 5277914 (1994-01-01), Szoka, Jr.
patent: 5366737 (1994-11-01), Eppstein et al.
patent: 5422344 (1995-06-01), Priel et al.
patent: 5552156 (1996-09-01), Burke
patent: 5736156 (1998-04-01), Burke
patent: 5958378 (1999-09-01), Waldrep et al.
patent: 6090407 (2000-07-01), Knight et al.
patent: 6346233 (2002-02-01), Knight et al.
patent: 4430593 (1994-08-01), None
patent: 0349127 (1990-01-01), None
patent: WO 93/18751 (1993-03-01), None
patent: WO 94/26253 (1994-05-01), None
patent: WO 96/05821 (1995-08-01), None
patent: WO 96/19199 (1995-12-01), None
patent: WO 98/00111 (1998-01-01), None
“Chiron submits new drug application for pulminiq; inhaled form of cyclosporine could be first immunosuppressant indicated for chronic lung-transplant rejection,” www.drugs.com
da/pulminiq—041014.html., Oct. 14, 2004.
Abang et al., “The clinical pharmacology of topoisomerase I inhibitors,”Sem Hematol, 35:13-21, 1998.
Ahmed et al., “Influence of route of administration on [3h]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies,”Cancer Chemother Pharmacol., 39:122-130, 1996.
Anderson, “Delivery systems for immunomodulatory proteins and peptides,”BioDrugs, 7:51-65, 1997.
Burckart et al., “Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients,”Pharmaceutical Research, 20:252-256, 2003.
Burke, “Lipid bilayer partitioning and stability of camptothecin drugs,”Biochemistry, 32:5352-5364, 1993.
Chourpa et al., “Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA,”Biochem, 37:7284-7291, 1998.
Fresta et al., “Evaluation and optimization of liposomes as delivery device for methotrexate,”Pharmazie, 47:926-929, 1992.
Garcia-Carbonero et al., “Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins,”Clin. Cancer Res., 8:641-661, 2002.
Giovanella et al., “Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin,”Cancer Res., 51:3052-3055, 1991.
Hallman et al., “Inositol supplementation in premature infants with respiratory distress syndrome,”N. Eng. J. Med., 326:1233-1239, 1992.
Hausheer et al., “Karenitecins: a novel, potent class of oral highly lipophillic topo I inhibitors,”Proc. Annu. Meet. Am. Asoc. Cancer Res., 38:A1526, 1997.
Hertzberg et al., “Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity,”J. Medic. Chem., 32:715-720, 1989.
Hinz et al., “Pharmacokinetics of the in Vivo and in Vitro Conversion of 9-Nitro-20(S)-camptothecin to 9-Amino-20(S)-camptothecin in Humans, Dogs, and Mice,”Cancer Res., 54:3096-3100, 1994.
Hochster et al., “Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen,”J. Clin. Oncol., 12:553-559, 1994.
Iacono et al., “Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans,”Eur. Respir. J., 23:384-390, 2004.
Kim et al., “Pharmacodynamics of insulin in polyethylene glycol-coated liposomes,”Int. J. Pharm., 180:75-81, 1999.
Knight et al., “New approaches in aerosol drug delivery for the treatment of asthma,” in Allergy and Allergic Diseases, Kay (ed), Blackwell Publications, Oxford, England, I:730-741.
Lesueur-Ginot et al., “Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties,”Cancer Res., 59:2939-2943, 1999.
Mi et al., “Reduced albumin binding promotes the stability and activity of topotecan in human blood,”Biochemistry, 34:13722-13728, 1998.
Ozer, “Stability studies of 5-FU liposomes,”Drug Targeting Delivery, 1:151-160, 1992.
Schreier et al., “Pulmonary delivery of liposomes,”J. Controlled Release, 24:209-223, 1993.
Sugarman et al., “Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies,”Cancer Chemother Pharmacol., 37:531-538, 1996.
Verschraegen et al., “A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor,”Anti-Cancer Drugs, 9:36-44, 1998.
Verschraegen et al., “Alternative administration of camptothecin analogues,”Ann NY Acad. Sciences, 922:237-246, 2000.
Waldrep et al., “Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition,”Int. J. Pharaceutics, 97:205-212, 1993.
Waldrep et al., “Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates,”J. Aerosol Med., 7:133-145, 1994.
Weibel, “Geometry and dimensions of airways of conductive and transitory zones,” In Morphometry of the Human Lungs, NY: Academic Press Inc., 110-140, 1963.
Zamboni et al., “Phase I and pharmacokinetic (PK) study of intermittently administered 9-nitro-campothecin (9NC, Rubitecan) in patients with advanced malignancies,”Proc. Am. Soc. Clin. Oncol., A411, 2001.
Gilbert Brian
Giovanella Beppino C.
Knight J. Vernon
Koshkina Nadezhda
Waldrep J. Clifford
Fulbright & Jaworski L.L.P.
Research Development Foundation
Sasan Aradhana
Woodward M P
LandOfFree
Small particle liposome aerosols for delivery of anti-cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small particle liposome aerosols for delivery of anti-cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small particle liposome aerosols for delivery of anti-cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3921373